

Polymorphisms in the Estrogen Receptor Beta Gene and the Risk of Unexplained Recurrent Spontaneous Abortion

Marzieh Mahdavi-pour ¹, Saeed Zarei ², Ramina Fatemi ¹, Haleh Edalatkhah ³, Hamed Heidari-Vala ³, Mahmood Jeddi-Tehrani ², and Farah Idali ^{1*}

1. Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

2. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

3. Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

Abstract

Background: Recurrent Spontaneous Abortion (RSA) is caused by multiple genetic and non-genetic factors. Around 50% of the RSA cases have no known etiology and are considered as Unexplained RSA (URSA). Estrogens, *via* binding to their receptors, play an important role in female reproduction. This study aimed to investigate whether single nucleotide polymorphisms (SNPs; +1082G/A, +1730G/A and rs1256030 C/T) in the estrogen receptor beta (*ESR2*) gene are associated with susceptibility to URSA in a population of Iranian women.

Methods: In this case-control study, the study groups consisted of 240 subjects with a history of URSA and 102 fertile women as controls. Serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) were measured on day 2-3 of menstrual cycle. Two functional SNPs, +1082G/A (a silent mutation in exon 5) and +1730G/A (3' untranslated region of the exon 8), and one intron, rs1256030C/T, in the *ESR2* gene were genotyped, using polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP) analysis.

Results: Serum levels of LH were significantly increased in URSA women. No significant differences in distribution of +1082G/A, +1730G/A and rs1256030C/T between URSA and control groups were observed.

Conclusion: Our findings suggest that the studied SNPs on *ESR2* gene may not be associated with URSA.

Avicenna J Med Biotech 2017; 9(3): 150-154

Keywords: Estrogen receptor, Habitual abortion, Polymerase chain reaction, Restriction fragment length polymorphism, Single-nucleotide polymorphism

Introduction

Recurrent Spontaneous Abortion (RSA) is a multifactorial disorder and in most cases, a single cause for repeated abortions cannot be identified. RSA is defined as repeated occurrence of 3 or more miscarriages before 20th week of gestation which affects about 0.5-1% of total pregnancies ¹. Diverse factors, including uterine anomalies, chromosomal abnormalities, endocrine and immune defects, thrombophilia and infections could be associated with increased risk of RSA ². In addition, at least half of the cases with RSA have no anomaly in any applied diagnostic test and are considered as cases with Unexplained RSA (URSA). With increase in the number of abortions, maternal factors that affect embryo-endometrial interactions may become more and more involved in pregnancy failures ³.

The role of hormones in reproductive events has been extensively investigated, and alterations in the

Hypothalamus-Pituitary-Ovarian (HPO) axis factors are shown to negatively affect fertility and pregnancy. Recent studies revealed that genetic polymorphisms affecting the function of genes involved in regulating HPO, could be associated with RSA ⁴.

Estrogens are steroid hormones that affect reproductive system in both female and male. Estrogens are mainly produced in ovaries and influence female reproduction in several aspects, including progesterone induction, endometrial proliferation and maintenance, fetoplacental function and maturation, as well as uteroplacental circulation ⁵.

Estrogen action is mediated by Estrogen Receptors (ERs). The ERs are ligand activated transcription factors and belong to the steroid/retinoid receptor gene super family that also includes receptors for androgens, progesterone, glucocorticoids, mineralocorticoids, as

* **Corresponding author:**
Farah Idali, Ph.D., Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran P.O.Box: 19615-1177, Postal code: 1936773493
Tel: +98 21 22432020
Fax: +98 21 22432021
E-mail: farahid@yahoo.com
Received: 19 Apr 2016
Accepted: 8 Aug 2016

Table1. Characteristics of studied SNPs on ESR2 gene

	+1082 G/A	+1730 G/A	rs1256030 C/T
Region	Exon5	3'UTR, exon 8	Intron 2
PCR primers Upstream	5'-TTGCGCAGCTTAACCTCAAA-3'	5'-GGTTTAGGGGTGGGGTAGACTG-3'	5'-CAATGCATATCCTGCCTGTG-3'
Downstream	5'-ACCTGTCCAGAACAAAGATCT-3'	5'-GTGGAGGGAAGGATGGTACA-3'	5'-TCCCGGAAATCTGATACAGC-3'
PCR product, bp	321 bp	442 bp	251 bp
Digestion	RsaI, 37°C	AluI, 37°C	AluI, 37°C
Allele size, bp	G: 321 ^A A: 211+110 ^B	G: 442 ^A A: 336+106 ^B	C: 227+ 24 ^A T: 80+147+24 ^B

A) RFLP product for normal allele; B) RFLP product for mutant allele

well as thyroid hormone, retinoic acid and vitamin D⁶. Two nuclear receptors for estrogen have been identified in humans; Estrogen Receptor α (ER α) and Estrogen Receptor β (ER β), coded by *ESR1* (located on chromosome 6q25.1) and *ESR2* (on chromosome 14q22-24) genes, respectively, each consisting of 8 exons. Although these two receptors have high homologies, they are expressed in a preferable but sometimes overlapping modes and display functional similarities as well as differences, sometimes even opposite actions⁷.

The essential roles of ER β in normal ovulation efficiency⁸ and in regulation of follicular growth and oocyte development⁹ are well documented, while ER α has a key role in fertilization⁸. The genetic variants of *ESR1* and *ESR2* genes and their associations with ovulatory dysfunction especially those with unknown causes and pregnancy outcomes^{10,11}, infertility and endometriosis¹²⁻¹⁴ have been investigated. The aim of this study was to examine the role of three Single Nucleotide Polymorphisms (SNPs) in the *ESR2* gene, including +1082G/A (a silent transition in exon 5), +1730G/A (3'untranslated region of the exon 8) and one intron (rs1256030 C/T in intron2) in URSA among Iranian population.

Materials and Methods

Subjects

In this case-control study, 240 women (mean age; 33.3 $\pm$ 0.4 years, BMI; 26.6 $\pm$ 0.3) were included as the case group, who suffered from at least three consecutive abortions before 20th week of gestation, and were referred to Avicenna Fertility Center, Tehran, Iran, for treatment of RSA. Standard diagnostic procedures including a detailed history, chromosomal analyses of peripheral blood lymphocytes, ultrasonography and hysterosalpinogography to detect uterine anomalies, hormone profiles on day 2-3 of the menstrual cycles, measurement of Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), and Estradiol (E2) as well as investigation of thrombophilia, infections and immune factors were performed for all patients. Patients with anatomical, chromosomal, infectious, endocrine, thrombophilia and autoimmune causes including antiphospholipid syndrome were excluded from the study.

The control group consisted of 102 healthy ethnically matched women (mean age; 39.2 $\pm$ 0.6 years, BMI;

27.5 $\pm$ 0.4) with two or more successful pregnancies and live births and no history of complicated pregnancies, miscarriages, still births, small gestational age fetuses, pre-eclampsia, ectopic pregnancy or preterm delivery.

The study was approved by Avicenna Research Institute's (ARI) local ethics committee for medical research, and written consents were obtained from participating subjects before entry into the study.

Biochemical assays

Serum level of E2 was measured by Enzyme Immunoassay (EIA) (Axis Shield, Dundee, UK). LH and FSH were measured by Chemiluminescent Immune Assays (CLIA) (Diasorin; Saluggia, Italy).

Single nucleotide polymorphism genotyping

Peripheral blood samples were obtained from all subjects and analyzed for *ESR2* gene polymorphisms; +1082G/A, +1730G/A and rs1256030C/T. Genomic DNA was extracted from anti-coagulated peripheral blood, using a standard salting out procedure¹⁵. Genotyping of the *ESR2* polymorphisms was determined by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP), using specific primers as shown in table1. PCR reaction mixtures contained 200 ng of DNA, 1xPCR Master Mix (Taq DNA Polymerase Master Mix Red, Ampliqon, Herlev, Denmark) and 10p moles of each specific primer. Annealing temperatures of 55.0°C for +1082G/A, 59.0°C for +1730G/A and 56.0°C for rs1256030C/T were used. The amplification cycles included 95°C for 5 min, followed by 35 cycles of 95°C for 30 s, 30 s for annealing and 72°C for 30 s and a final elongation time of 72°C for 5 min. PCR products were then digested by restriction endonucleases RsaI for +1082G/A, AluI for +1730G/A and rs1256030C/T (Fermentas, Vilnius, Lithuania) for 3 hr at 37°C (Table1). Restriction endonuclease fragments were blended with gel red (Biotium, CA, USA) and then applied on to a 2-2.5% agarose gel and electrophoresed. Detection was made by visualization on an ultraviolet light transilluminator.

Statistical analysis

All statistical analyses were carried out with SPSS software package 16.0 (SPSS Inc., USA). The distributions of polymorphisms were compared between groups using Mann-Whitney U test. T-test was used to com-

ESR2 Polymorphism in Unexplained Recurrent Spontaneous Abortion

Table 2. The hormone profiles of control and URSA women on day 2-3 of the menstrual cycles

Characteristics	Controls	URSA	p-value [†]
Estradiol (pg/ml)	44.5±6.0	37.4±3.6	NS
FSH (IU/ml)	7.0±0.4	7.5±0.3	NS
LH (IU/ml)	3.0±1.4	4.5±0.2	p<0.001

[†] Determined by t- test. The data is presented as mean±SEM.
NS, not significant

pare hormone levels between the groups. For comparisons between different genotypes and the levels of investigating hormones one way ANOVA was used. Correlations between different genotypes were determined with Spearman's rank correlation test. Data was presented as mean±SEM and p-values <0.05 were regarded as significant.

Results

Table 2 summarizes the hormone profiles of the study subjects. There were no significant differences between URSA and control groups in levels of E2 and FSH. Serum LH levels in the URSA group (although within normal range) were significantly higher than that in the controls (p<0.001).

The genotype frequencies of all subjects are shown in table 3. The frequency of +1082G/A polymorphism showed a weak trend to be significantly different in URSA compared to that in the control group (p=0.082). A homozygous +1082AA genotype was not found in any group. No significant differences in the genotype frequencies of +1730G/A and rs1256030C/T polymorphisms between the studied groups were observed (p=0.519 and p=0.936, respectively).

Also, the subjects were further grouped into wild type, heterozygotic and homozygotic genotypes and the serum hormone levels within those groups were compared (Table 4). No statistically significant differences between the serum levels of measured hormones and the genotypes of the studied genetic polymorphisms were detected. However, a trend to lower serum FSH levels in women with the GA and AA genotypes compared with those with GG genotype of the *ESR2*+1730G/A was detected (p=0.063) (Table 4). In addition, in +1730G/A polymorphism, GA and AA genotypes also showed a trend to higher E2 compared to GG genotype (p=0.079) (Table 4).

By using Spearman's rank correlation test, correlations between investigated polymorphisms were estimated. A negative correlation was found between polymorphisms; +1082G/A and +1730G/A (r=-0.137, p=0.012). In addition, a positive correlation between +1730G/A and rs1256030C/T polymorphisms was detected (r=0.164, p=0.003). After subdividing case and control groups, the positive correlation between +1730G/A and rs1256030C/T polymorphisms was only found in the control group (r=0.352, p<0.001) and the negative correlation between +1082G/A and +1730

Table 3. Genotype frequencies of ESR2 gene polymorphisms in URSA and control groups

Polymorphism	URSA, no (%)	Control, no (%)	p-value [†]
+1082G/A(rs1256049)	n=237	n=102	
GG	218(92%)	99(97.1%)	0.082
GA	19(8%)	3(2.9%)	
AA	0.0%	0.0%	
+1730 G/A(rs4986938)	n=235	n=102	
GG	104(44.2%)	48(47%)	0.519
GA	108(46%)	32(31.4%)	
AA	23(9.8%)	22(21.6%)	
rs1256030 C/T	n=238	n=99	
CC	56(23.5%)	27(27.3%)	0.936
CT	110(46.2%)	38(38.4%)	
TT	72(30.3%)	34(34.3%)	

[†] Determined by Mann-Whitney U-test

Table 4. The hormone profiles of wild type, heterozygotic and homozygotic genotypes of ESR2 polymorphisms

	Wild type	Heterozygous	Homozygous	p-value [*]
Estradiol (pg/ml)				
+1082G/A	40.1±3.1	27.3±11.4	-	0.321
+1730 G/A	33.1±3.1	42.9±4.9	55.0±16.5	0.079
rs1256030 C/T	47.0±7.2	38.1±4.1	35.2±5.7	0.346
FSH (IU/ml)				
+1082G/A	7.3±0.2	8.4±0.8	-	0.301
+1730 G/A	7.8±0.3	7.3±0.4	6.0±0.5	0.063
rs1256030 C/T	7.3±0.4	7.7±0.4	6.8±0.3	0.296
LH (IU/ml)				
+1082G/A	4.1±0.2	5.5±0.8	-	0.099
+1730 G/A	4.1±0.4	4.3±0.2	3.7±0.6	0.722
rs1256030 C/T	3.9±0.4	4.2±0.3	4.2±0.4	0.790

Data presented as mean±SEM.

^{*}Determined by one way ANOVA.

G/A was only found in the URSA group (r=-0.155, p=0.017).

Discussion

RSA is recognized as a syndrome with a multifactorial etiology. At least, 50% of RSA cases were defined as RSA with unexplained origin. Investigating genes and biological mechanisms that can affect miscarriage may have beneficial effects on increasing live birth rates in cases suffering from URSA. Through investigating polymorphic genetic markers, a number of candidate genes for this syndrome have been identified. Genetic variation concerning thrombophilic and vascular genes is reported as a significant contributor to pregnancy complications^{2,16-18}. Polymorphisms in the estrogen receptor genes could affect different estrogen dependent pathways which may influence vascular tone and flow, leading to disruption of pregnancy maintenance. Role of *ESR* gene polymorphisms in increasing the risk of RSA has been investigated and most of the studies considered the involvement of

ESR1 gene polymorphism in this process¹⁹⁻²¹. The role of *ESR2* gene polymorphisms in RSA was investigated in Brazil population, in 75 women with a history of RSA and 139 controls; in China population, in 196 women with RSA and 182 controls; and in Korean women, in 305 RSA women and 299 controls^{20,22,23}. No association between +1730G/A and +1082G/A polymorphisms with the syndrome was reported. Here, an attempt was made to search for a relation between three *ESR2* gene polymorphisms and URSA in Iranian women, a different ethnic group from above mentioned groups. But, no association between +1730G/A, +1082G/A and rs1256030C/T polymorphisms and URSA could be shown. However, our study showed a trend to significant differences in +1082G/A polymorphism between URSA and control women.

Regarding the +1082G/A polymorphism, only two genotypes (GG and GA) were present in our study subjects which is in line with the study by Alessio *et al* who neither reported the presence of +1082AA in Caucasian controls nor in the RSA patients²⁰. Looking into genotypes and ethnicity, there are notable ethnic differences in the genotype distribution of +1082G/A polymorphism between Asians and Caucasians. Results from the present study showed that, similar to *ESR1* polymorphism study²¹, the prevalence of Iranian genotype is more like Caucasians^{4,20}, which is different from Asians^{10,22}.

Considering the importance of studying +1082G/A and +1730G/A polymorphisms in *ESR2* gene, although such polymorphisms do not lead to amino acid changes in the ER β protein, it is possible that these polymorphisms are in linkage disequilibrium with different regulatory sequence variations that may influence gene expression or function²⁴. Alternatively, some studies explained the functional influence of 3'-UTR-located SNPs on gene expression and local RNA structure and considered them as the cause of disease-related SNPs in non-protein-coding transcribed sequences²⁵. In addition, 3'-UTRs of a large number of protein-coding genes are shown to be objects for microRNAs. But, none of them happened on the 3'-UTR sequences of *ESR2* gene where +1730G/A is placed, although such microRNA may be present, but remains to be detected.

Furthermore, an intronic mutation may influence variable splicing and lead to a different final protein. In this regard, the intronic rs1256030C/T polymorphism has been associated with the urinary excretion levels of LH²⁶ and elevated risk of ovarian cancer²⁷. However, no association was found between this SNP and URSA.

Endocrinological abnormalities are present in about a quarter of women with unexplained recurrent miscarriage²⁸. In our study, although the URSA women had LH levels within laboratory normal serum range, a significant difference in the serum levels of LH was found between URSA and controls. Such findings confirm previous reports that hypersecretion of LH is associated with early pregnancy loss^{29,30}. However, ge-

netic variants of the studied polymorphisms showed no significant association with the levels of LH. Lower amount of FSH might be harmful for ovulation induction. Here, a trend to higher E2 and lower FSH levels was found in women with the +1730 AA genotypes. In these women, the increased serum E2 level may suppress the pituitary in producing FSH. This finding may indicate the significance of screening URSA women for this SNP. This genotype has been suggested to be included in a screening panel for assessment of cardiovascular risk in menopausal women³¹.

Conclusion

In conclusion, our data suggest that *ESR2* gene in +1082G/A, +1730G/A and rs1256030C/T polymorphisms may not be involved with the risk of URSA, although further investigations regarding +1082G/A and +1730G/A genotypes are required to establish a role for URSA.

Acknowledgement

We are grateful to the women who entered this study. We greatly appreciate the assistance of the personnel of Avicenna Fertility Center in sample collection. This work was supported by grants from Avicenna Research Institute (Grant no: 90-16), Tehran, Iran.

Conflict of Interest

The authors declare that they have no conflict of interests.

References

1. Baek KH. Aberrant gene expression associated with recurrent pregnancy loss. *Mol Hum Reprod* 2004;10(5): 291-297.
2. Idali F, Zareii S, Mohammad-Zadeh A, Reihany-Sabet F, Akbarzadeh-Pasha Z, Khorram-Khorshid HR, et al. Plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase gene mutations in Iranian women with polycystic ovary syndrome. *Am J Reprod Immunol* 2012;68(5):400-407.
3. Ogasawara M, Aoki K, Okada S, Suzumori K. Embryonic karyotype of abortuses in relation to the number of previous miscarriages. *Fertil Steril* 2000;73(2):300-304.
4. Hanna CW, Bretherick KL, Liu CC, Stephenson MD, Robinson WP. Genetic variation within the hypothalamus-pituitary-ovarian axis in women with recurrent miscarriage. *Hum Reprod* 2010;25(10):2664-2671.
5. Albrecht ED, Aberdeen GW, Pepe GJ. The role of estrogen in the maintenance of primate pregnancy. *Am J Obstet Gynecol* 2000;182(2):432-438.
6. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. *Annu Rev Biochem* 1994;63:451-486.
7. Nilsson S, Gustafsson JA. Estrogen receptor transcription and transactivation: Basic aspects of estrogen action. *Breast Cancer Res* 2000;2(5):360-366.

8. Hewitt SC, Korach KS. Oestrogen receptor knockout mice: roles for oestrogen receptors alpha and beta in reproductive tissues. *Reproduction* 2003;125(2):143-149.
9. Hosokawa K, Ottander U, Wahlberg P, Ny T, Cajander S, Olofsson IJ. Dominant expression and distribution of oestrogen receptor beta over oestrogen receptor alpha in the human corpus luteum. *Mol Hum Reprod* 2001;7(2):137-145.
10. Sundarajan C, Liao WX, Roy AC, Ng SC. Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. *J Clin Endocrinol Metab* 2001;86(1):135-139.
11. Sheikhha MH, Kalantar SM, Aflatoonian A. The relationship between estrogen receptor alpha gene polymorphism and ovarian response to ovulation induction in women under IVF treatment. *J Reprod Infertil* 2007;7(4):315-323.
12. Zulli K, Bianco B, Mafra FA, Teles JS, Christofolini D M, Barbosa CP. Polymorphism of the estrogen receptor β gene is related to infertility and infertility-associated endometriosis. *Arq Bras Endocrinol Metabol* 2010;54(6):567-571.
13. Govindan S, Shaik NA, Vedicherla B, Kodati V, Rao K P, Hasan Q. Estrogen receptor-alpha gene (T/C) Pvu II polymorphism in endometriosis and uterine fibroids. *Dis Markers* 2009;26(4):149-154.
14. Christofolini DM, Vilarino FL, Mafra FA, Andre GM, Bianco B, Barbosa CP. Combination of polymorphisms in luteinizing hormone β , estrogen receptor β and progesterone receptor and susceptibility to infertility and endometriosis. *Eur J Obstet Gynecol Reprod Biol* 2011;158(2):260-264.
15. Rousseau F, Réhel R, Rouillard P, DeGranpré P, Khandjian EW. High throughput and economical mutation detection and RFLP analysis using a minimethod for DNA preparation from whole blood and acrylamide gel electrophoresis. *Hum Mutat* 1994;4(1):51-54.
16. Jeddi-Tehrani M, Torabi R, Zarnani AH, Mohammadzadeh A, Arefi S, Zeraati H, et al. Analysis of plasminogen activator inhibitor-1, integrin beta3, beta fibrinogen, and methylenetetrahydrofolate reductase polymorphisms in Iranian women with recurrent pregnancy loss. *Am J Reprod Immunol* 2011;66(2):149-156.
17. Tempfer CB, Jirecek S, Riener EK, Zeisler H, Denschlag D, Hefler L, et al. Polymorphisms of thrombophilic and vasoactive genes and severe preeclampsia: a pilot study. *J Soc Gynecol Invest* 2004;11(4):227-231.
18. Soltanghorae H, Memariani T, Aarabi M, Hantoush-zadeh S, Arefi S, Aarabi M, et al. Association of ACE, PAI-1 and coagulation factor XIII gene polymorphisms with recurrent spontaneous abortion in Iranian patients. *J Reprod Infertil* 2007;7(4):324-330.
19. Aléssio AM, Höehr NF, Siqueira LH, Ozelo MC, de Pádua Mansur A, Annichino-Bizzacchi JM. Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis. *Thromb Res* 2007;120(5):639-645.
20. Aléssio AM, Siqueira LH, de Carvalho EC, Barini R, Mansur Ade P, Höehr NF, et al. Estrogen receptor alpha and beta gene polymorphisms are not risk factors for recurrent miscarriage in a Brazilian population. *Clin Appl Thromb Hemost* 2008;14(2):180-185.
21. Mahdavi-pour M, Idali F, Zarei S, Talebi S, Fatemi R, Jeddi-Tehrani M, et al. Investigation on estrogen receptor alpha gene polymorphisms in Iranian women with recurrent pregnancy loss. *Iran J Reprod Med* 2014;12(6):395-400.
22. Hu J, Wang J, Xiang H, Li Z, Wang B, Cao Y, et al. Association of polymorphisms in the estrogen receptor β (ESR2) with unexplained recurrent spontaneous abortion (URSA) in Chinese population. *J Matern Fetal Neonatal Med* 2012;25(9):1727-1729.
23. Kim JJ, Choi YM, Lee SK, Yang KM, Paik EC, Jeong H J, et al. Estrogen receptor beta gene polymorphisms and risk of recurrent pregnancy loss: a case-control study. *Gynecol Endocrinol* 2015;31(11):870-873.
24. Yaich L, Dupont WD, Cavener DR, Parl FF. Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. *Cancer Res* 1992;52(1):77-83.
25. Haas U, Sczakiel G, Laufer SD. MicroRNA-mediated regulation of gene expression is affected by disease-associated SNPs within the 3'-UTR via altered RNA structure. *RNA Biol* 2012;9(6):924-937.
26. Sowers MR, Jannausch ML, McConnell DS, Kardia SR, Randolph JF Jr. Menstrual cycle markers of ovarian aging and sex steroid hormone genotypes. *Am J Med* 2006;119(9 Suppl 1):S31-43.
27. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, et al. Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma. *Cancer Causes Control* 2009;20(1):47-55.
28. Li TC, Spuijbroek MD, Tuckerman E, Anstie B, Loxley M, Laird S. Endocrinological and endometrial factors in recurrent miscarriage. *BJOG* 2000;107(12):1471-1479.
29. Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. *Hum Reprod* 1994;9(7):1328-1332.
30. Chandler CJ. Hypersecretion of luteinising hormone: a significant cause of infertility and miscarriage. *Br J Obstet Gynaecol* 1994;101(8):737-738.
31. Marini H, Currò M, Adamo EB, Polito F, Ferlazzo N, Bitto A, et al. The ESR2 Alu1730G>A (rs4986938) gene polymorphism is associated with fibrinogen plasma levels in postmenopausal women. *Gene* 2012;508(2):206-210.